South Korea Next-Generation Biologics Market Size, Share, Growth, and Industry Analysis, By Product Type (Antibody Drug Conjugates, Bispecific Antibodies, Fusion Protein Therapeutics, Monoclonal Antibody Fragments  ), By Disease Area (Oncology, Autoimmune and Inflammatory Disorders, Genetic Disorders , Infectious Diseases  ) and Forecast, 2026-2034

South Korea Next-Generation Biologics Market Trends

Advanced antibody engineering and multimodal manufacturing reshape pipelines

South Korean developers are shifting toward ADCs, multispecific antibodies, next-generation vaccines, and complex conjugation platforms. Celltrion plans 13 innovative-drug IND submissions by 2028 and has prioritized ADCs and multispecific antibodies, while CT-P72 demonstrated a reported 180-fold safety advantage versus a comparator in preclinical evaluation. Samsung Biologics has simultaneously added dedicated ADC services, linking antibody manufacturing, process engineering, development, and conjugation.

Manufacturing infrastructure is scaling with this technology transition. Songdo's biopharmaceutical capacity reached approximately 1.035 million liters in 2025 and is projected around 2.14 million liters by 2030, more than doubling in five years. SK bioscience's KRW 377.2 billion Global R&PD Center began operations in January 2026, while its FY2025 consolidated revenue increased 144% to KRW 651.4 billion. These investments strengthen demand for high-titer cell culture, conjugation, process development, analytical testing, and flexible manufacturing systems.

South Korea Next-Generation Biologics Market Drivers

Expanding biomanufacturing capacity and R&D investment accelerate commercialization

Domestic bioindustry production increased 9.8% in 2024, exports advanced 17.1%, and investment climbed 46.1%, including a 145.3% surge in facility investment and 3.2% increase in R&D spending. Songdo capacity is projected to rise from 1.035 million liters in 2025 to 2.14 million liters by 2030, while LOTTE BIOLOGICS is developing three 120,000-liter plants for a planned 360,000-liter campus. These capacity additions support larger clinical-to-commercial programs across antibodies, ADCs, recombinant proteins, and other complex biologics.

South Korea Next-Generation Biologics Market Restraints

Complex manufacturing and regulatory requirements raise development risk

Advanced therapies require specialized vectors, cell systems, analytical controls, and validated scale-up processes. Research comparing expedited gene-therapy pathways identified only 3 expedited programs in South Korea versus 5 in the United States and 4 in the EU; the study identified just 3 gene-therapy approvals in South Korea compared with 13 in the U.S. and 14 in the EU. Such regulatory and manufacturing complexity can extend development timelines and elevate per-program capital requirements.

South Korea Next-Generation Biologics Market Opportunities

Integrated CDMO infrastructure creates opportunities in emerging modalities

Large-scale infrastructure creates opportunities to combine antibody production with ADC conjugation, cell-line development, analytics, and fill-finish services. LOTTE's Songdo Plant 1 provides planned capacity of 120,000 liters through eight 15,000-liter bioreactors, while the full campus is designed for 360,000 liters. Separately, Merck announced an investment exceeding EUR 300 million, approximately USD 326 million, in Daejeon to support biotechnology customers working on vaccines and cell-, gene-, and protein-based therapies.

Challenges in South Korea Next-Generation Biologics Market

Rapid capacity additions increase pressure on utilization, talent, and technology differentiation

Songdo capacity is expected to move from 1.035 million liters in 2025 toward 2.14 million liters in 2030, while LOTTE alone plans 360,000 liters across three facilities. Concurrently, Korean bioindustry facility investment expanded 145.3% in 2024 and total investment rose 46.1%. Maintaining high utilization, specialized technical staffing, GMP compliance, and competitive manufacturing economics therefore becomes increasingly important as domestic capacity expands faster than historical levels.

South Korea Next-Generation Biologics Market Segmentation

The market is segmented by product type, disease area, manufacturing platform, route of administration, and distribution channel. In 2026, ADCs account for approximately 23.8% of product revenue, while oncology and autoimmune/inflammatory disorders each represent approximately 28.4% of the disease-area total.

By Product Type

Antibody drug conjugates are the largest product category, increasing from USD 0.35 billion in 2026 to USD 0.81 billion by 2034 at a 10.92% CAGR. Bispecific antibodies follow at USD 0.22 billion in 2026 and USD 0.51 billion in 2034, while fusion protein therapeutics rise from USD 0.20 billion to USD 0.45 billion.

Nanobodies and single-domain antibodies and Others register the fastest listed CAGR of 11.21%. RNA-based biologics expand at 11.19%, engineered cytokines at 11.08%, and cell-based therapies at 11.06%, demonstrating relatively balanced expansion across emerging modalities.

By Disease Area

Oncology is the largest category alongside autoimmune and inflammatory disorders at USD 0.42 billion each in 2026. Oncology reaches USD 0.99 billion by 2034 at an 11.18% CAGR, compared with USD 0.95 billion and 10.67% for autoimmune and inflammatory disorders.

Oncology records the fastest listed disease-area CAGR at 11.18%, narrowly exceeding genetic disorders at 11.17% and infectious diseases at 11.10%. Genetic disorders increase from USD 0.18 billion in 2026 to USD 0.41 billion in 2034.

By Manufacturing Platform

Manufacturing is segmented into mammalian cell culture, microbial systems, cell-free expression systems, viral vectors, RNA synthesis platforms, and others. Numerical subsegment values and CAGR figures for this segmentation were not supplied; therefore, no unsupported market sizing is introduced.

Mammalian systems remain operationally important for complex antibodies, while viral-vector and RNA platforms address newer modalities. The supplied dataset does not establish a numerical largest or fastest-growing manufacturing subsegment.

By Route of Administration

Routes include intravenous, subcutaneous, intramuscular, intrathecal/intraocular, and others. No route-specific revenue or CAGR values were provided, preventing defensible percentage allocation among the 5 listed categories.

Technology development increasingly emphasizes patient convenience and targeted delivery, but the supplied numerical dataset does not identify the largest or fastest-growing route.

By Distribution Channel

Distribution comprises hospital pharmacies, specialty pharmacies, retail pharmacies, and others. The dataset identifies 4 channels but provides no channel-specific revenue, percentage contribution, or CAGR.

Given the specialist handling requirements of complex biologics, institutional and specialty channels remain strategically relevant; however, numerical channel rankings cannot be established from the mandatory dataset.

South Korea Next-Generation Biologics Market Outlook

South Korea represents 100% of the geographic market analyzed, valued at approximately USD 1.47 billion in 2026 and forecast at USD 3.38 billion by 2034. Within the country, Incheon/Songdo is the principal large-scale biomanufacturing concentration: Songdo capacity stood at approximately 1.035 million liters in 2025 and is projected at 1.155 million liters during 2026 and 2.14 million liters by 2030.

The national ecosystem includes 18 operating bio clusters, including Songdo for biopharmaceuticals/CMO, Osong for biopharmaceuticals and medical technology, Daejeon for biotechnology ventures and advanced manufacturing, and Andong for vaccines. Market-share percentages by province are not contained in the supplied dataset and are therefore not fabricated; production infrastructure nevertheless indicates substantial concentration in Incheon, with additional research and manufacturing contributions from Chungcheong, Daejeon, Gyeonggi, and Gyeongbuk.

Top players in South Korea Next-Generation Biologics Market

• Samsung Biologics
• Celltrion
• SK bioscience
• LOTTE BIOLOGICS
• Samsung Bioepis
• GC Biopharma
• Hanmi Pharmaceutical
• Yuhan Corporation
• LigaChem Biosciences
• Alteogen
• ABL Bio
• Genexine
• Chong Kun Dang
• Dong-A ST
• CHA Biotech

Top two companies

• Samsung Biologic

:Company-specific percentage share of the defined national market is not publicly established in the supplied dataset. Its competitive positioning is nevertheless reinforced by the 2025 launch of dedicated ADC services and continued expansion of Bio Campus II. Songdo's overall cluster capacity exceeded 1.0 million liters in 2025, while Samsung's modality strategy extends beyond conventional antibody manufacturing toward ADC development and conjugation. In July 2026, Samsung also announced an approximately USD 1.8 billion acquisition of PolyPeptide Group, extending manufacturing capabilities into peptide therapeutics and diversifying its technology base.

• Celltrion

A defensible company-specific percentage share is likewise unavailable for this narrowly defined market. Celltrion's positioning centers on internal innovative-drug development across ADCs and multispecific antibodies, with a stated target of 13 IND submissions by 2028. Its CT-P72 program progressed from 2025 preclinical disclosure to U.S. FDA Phase 1 IND authorization in December 2025, while additional programs include CT-P70 and CT-P71. The pipeline strategy gives Celltrion direct exposure to oncology-focused advanced antibodies as it moves beyond its established biosimilar portfolio.

Recent Developments in South Korea Next-Generation Biologics Market

• 2026:Samsung Biologics announced an approximately USD 1.8 billion agreement to acquire PolyPeptide Group, adding peptide manufacturing capabilities; the transaction was expected to close by the end of 2026 subject to approvals.
• 2026:SK bioscience commenced operations at its Songdo Global R&PD Center following KRW 377.2 billion of investment, strengthening integrated research and process-development capabilities.
• 2025:Celltrion reported CT-P72 preclinical results showing a 180-fold safety advantage against a comparator and targeted an IND submission during 2025.
• 2025:LOTTE BIOLOGICS advanced Songdo Plant 1, designed for 120,000 liters of manufacturing capacity, as part of a three-plant campus planned for 360,000 liters.
• 2025:Samsung Biologics commenced dedicated ADC services and expanded collaboration with LigaChem Biosciences, combining antibody manufacturing expertise with development and conjugation capabilities.

Research Methodology

The assessment applies 2025 as the base year, 2026 as the current year, historical review across 2022–2024, and forecasting through 2034. Mandatory supplied values were retained without alteration: the product-type dataset totals USD 1.34 billion in 2025, USD 1.47 billion in 2026, and USD 3.38 billion in 2034, with a 10.88% CAGR. Percentage contributions were calculated directly from supplied totals, while external official and corporate sources were used only for contextual production capacity, investment, pipeline, regulatory, and recent-development indicators. No unsupported numerical estimates were inserted where segment or company-level data were unavailable.